Search Results for: LAM Therapeutics Announces Progress of
Articles
Denali Therapeutics Announces Strategic Partner Takeda Exercises Option to Co-Develop & Co-Commercialize Brain-Penetrant Progranulin Replacement Therapy November 17, 2021
Denali Therapeutics Inc. recently announced its strategic partner Takeda Pharmaceutical Company Limited has exercised an option, pursuant to an existing...Yumanity Therapeutics Announces Positive Top-Line Results of Phase 1b Clinical Trial for YTX-7739 in Patients With Parkinson’s Disease November 10, 2021
Yumanity Therapeutics recently reported its lead product candidate, YTX-7739, in development for the treatment of Parkinson’s disease, achieved its primary...Viking Therapeutics Announces Initiation of Phase 1b Clinical Trial of VK0214 in Patients With X-ALD June 29, 2021
Viking Therapeutics, Inc. recently announced the initiation of a Phase 1b clinical trial of VK0214, a novel small molecule agonist of the thyroid hormone receptor beta (TRb), in patients with X-linked….
ImCheck Announces Initiation of US Enrollment in Phase 1/2a EVICTION Trial for ICT01 April 29, 2021
ImCheck Therapeutics recently announced the first patient in the US has been dosed at the Yale University Cancer Center in...AC Immune Announces New Clinical Results in Down Syndrome, Plans for Future Development of Anti-Amyloid-Beta Vaccine March 17, 2021
AC Immune SA recently announced plans to advance its novel anti-amyloid-beta (Abeta) vaccine into mid-stage clinical testing to treat and...Orgenesis Announces Agreement to Acquire Koligo Therapeutics September 29, 2020
Orgenesis Inc. and Koligo Therapeutics, Inc. recently announced the two companies have entered into a definitive merger agreement, subject to final closing conditions, with expected completion….
NGM Bio Announces Initiation of Phase 2 CATALINA Study July 27, 2020
NGM Biopharmaceuticals, Inc. recently announced it has initiated the Phase 2 CATALINA study, a multicenter, randomized, double-masked, sham-controlled clinical trial, to evaluate the safety and efficacy of….
MediciNova Announces Opening of IND for MN-166 for Prevention of Acute Respiratory Distress Syndrome in Patients With COVID-19 July 1, 2020
MediciNova, Inc. recently announced that the Investigational New Drug Application (IND) for MN-166 (ibudilast) for prevention of Acute Respiratory Distress...Leading BioSciences Announces Potential for Investigational Drug to Treat Multiple Organ Dysfunction Syndrome in COVID-19 Patients April 9, 2020
Leading BioSciences recently announced it has developed a potential approach to treat COVID-19 patients suffering from acute respiratory distress syndrome (ARDS) and multiple organ dysfunction syndrome (MODS) using its….
Flexion Announces Clearance of NDA for Gene Therapy Candidate October 31, 2019
Flexion Therapeutics, Inc. recently announced clearance of the company’s Investigational New Drug (IND) application for FX201 in knee osteoarthritis.
Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials October 29, 2019
Menlo Therapeutics Inc. recently announced it has completed enrollment of patients in its two Phase 3 clinical trials evaluating the...Innovate Biopharmaceuticals Announces First Patient Dosed in the First Phase 3 Clinical Trial August 14, 2019
Innovate Biopharmaceuticals, Inc. recently announced it has dosed the first patient in its Phase 3 clinical trial, CeD LA 3001....Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study August 7, 2019
Oncternal Therapeutics, Inc. recently announced it has opened for enrollment its randomized Phase 2 study of cirmtuzumab, a ROR1-targeted monoclonal...Cara Therapeutics Announces Initiation of Phase 2 Trial of Oral KORSUVA June 26, 2019
Cara Therapeutics, Inc. recently announced the initiation of a Phase 2 trial of Oral KORSUVA (CR845/difelikefalin) for the treatment of...Owlstone Medical Announces a Novel Approach to Breath-Based Testing June 19, 2019
Owlstone Medical, the global leader in Breath Biopsy for applications in early disease detection and precision medicine, recently announced the...Adynxx Announces Merger Agreement With Alliqua BioMedical April 25, 2019
Adynxx, Inc. recently provided a business and clinical development update. Adynxx entered into a merger agreement with Alliqua Biomedical, Inc....BrainStorm Announces First Contracted US Clinical Site for Phase 2 Progressive MS Study February 22, 2019
BrainStorm Cell Therapeutics Inc. recently announced Cleveland Clinic as the first US clinical site contracted for a planned Phase 2...Jupiter Orphan Therapeutics Announces IND Submission for Mucopolysaccharidosis Type-I March 16, 2018
Jupiter Orphan Therapeutics, Inc. recently announced it had submitted its IND to the FDA on March 12, 2018 for Mucopolysaccharidosis Type-I (MPSI). This will be the first of several anticipated IND submissions in 2018 utilizing JOT’s platform product,JOTROL.
Jupiter Orphan Therapeutics Announces IND Submission for Mucopolysaccharidosis Type-I March 14, 2018
Jupiter Orphan Therapeutics, Inc. recently announced it had submitted its IND to the FDA on March 12, 2018 for Mucopolysaccharidosis...Akari Therapeutics Announces Completion of Phase II Trial February 13, 2018
Akari Therapeutics, Plc recently announced additional data for its Phase II COBALT clinical trial and provides an update on other...
